Effective testosterone suppression for prostate cancer: is there a best castration therapy?
Achieving and maintaining effective suppression of serum testosterone levels in men treated with androgen ablation is one of the essential strategies in the management of prostate cancer. Historically, a serum testosterone below 50 ng/dL was considered to be the castrate level. Current data suggest that the new target for either surgical or chemical castration is a serum testosterone level of lower than 20 ng/dL in an attempt to maximize therapeutic outcomes. Testosterone breakthrough and the acute-on-chronic effects of administration of a luteinizing hormone-releasing hormone analogue may cause testosterone levels to periodically rise, sometimes to noncastrate levels. The goal of androgen ablation is to identify those agents that will most consistently achieve and maintain the lowest testosterone levels possible.
Gomella
Leonard G
LG
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University Philadelphia, PA.
Lancet. 2000 Apr 29;355(9214):1491-8
10801170
J Urol. 2002 Feb;167(2 Pt 2):948-51; discussion 952
11905923
Urol Int. 2003;70(4):316-20
12740498
Urology. 2004 Dec;64(6):1177-81
15596193
N Engl J Med. 1989 Aug 17;321(7):419-24
2503724
Trends Endocrinol Metab. 2009 Jan;20(1):43-50
19008119
J Clin Endocrinol Metab. 1995 Nov;80(11):3209-22
7593428
Int J Gynaecol Obstet. 1980;18(5):318-24
6110575
BJU Int. 2007 Jan;99 Suppl 1:19-22; discussion 23-4
17229164
Scand J Urol Nephrol. 1992;26(1):11-4
1631501
Biochem Biophys Res Commun. 1975 Nov 17;67(2):576-82
1106409
Cancer. 1973 Nov;32(5):1126-30
4585929
Curr Opin Urol. 2000 Sep;10(5):415-20
11005445
Reprod Biomed Online. 2009 Jan;18(1):9-14
19146763
Lancet Oncol. 2006 Jun;7(6):472-9
16750497
Curr Opin Urol. 2009 May;19(3):322-6
19318949
Clin Cancer Res. 2007 Jan 1;13(1):241-5
17200361
Curr Med Res Opin. 2007 May;23(5):1077-80
17519074
Clin Cancer Res. 2007 Jul 1;13(13):4027
17606739
N Engl J Med. 1998 Oct 8;339(15):1036-42
9761805
J Urol. 2002 Sep;168(3):1001-4
12187208
Urol Int. 1998;60(1):33-40
9519419
Urology. 2000 Dec 20;56(6):1021-4
11113751
J Clin Oncol. 2007 Apr 20;25(12):1596-605
17404365
Cleve Clin J Med. 2007 May;74 Suppl 3:S38-46
17549824
J Urol. 2000 Sep;164(3 Pt 1):726-9
10953134
Eur Urol. 2006 Jan;49(1):54-8; discussion 58
16314038
BJU Int. 2003 Aug;92(3):226-31
12887472
J Clin Oncol. 2006 Aug 20;24(24):3984-90
16921051
Clin Genitourin Cancer. 2007 Sep;5(6):371-8
17956709
Urology. 1994 Jun;43(6):834-7
8197647
BJU Int. 2008 Dec;102(11):1531-8
19035858
JAMA. 2005 Jul 13;294(2):238-44
16014598
N Engl J Med. 1997 Jul 31;337(5):295-300
9233866
J Urol. 2007 Oct;178(4 Pt 1):1290-5
17698136
J Urol. 1997 Oct;158(4):1623-4
9302187
Urology. 2009 May;73(5 Suppl):S28-35
19375624
Prostate Cancer Prostatic Dis. 2009;12(1):88-93
18574490
J Urol. 2002 Feb;167(2 Pt 1):535-8
11792913
J Urol. 1973 May;109(5):858-60
4699685
Urology. 2001 Aug;58(2 Suppl 1):5-9
11502435